Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Estudio multicéntrico para evaluar el resultado clínico del implante PrimeTaper EV en restauraciones de un solo diente

11 de septiembre de 2026 actualizado por: Dentsply Sirona Implants and Consumables

Una investigación abierta, prospectiva y multicéntrica para evaluar el resultado clínico del implante PrimeTaper EV en alvéolos de extracción y crestas cicatrizadas: seguimiento de 5 años

The purpose of this study is to evaluate the clinical outcome of implant survival of the PrimeTaper EV implant in single tooth restorations 1 year after permanent restoration.

Descripción general del estudio

Estado

Activo, no reclutando

Intervención / Tratamiento

Tipo de estudio

Intervencionista

Inscripción (Actual)

138

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

      • Alzey, Alemania, DE-55232
        • Dental practice Dr Mischa Krebs
      • Leuven, Bélgica, B-3000
        • Catholic University of Leuven
    • Iowa
      • Iowa City, Iowa, Estados Unidos, 52242-1010
        • University of Iowa
      • Busto Arsizio, Italia, IT-21052
        • Studio Toia
      • Apeldoorn, Países Bajos, 7315CA
        • Dr.F.L.Guljé, De Mondhoek

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 75 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Adult aged 18-75 years.
  • Willing and able to sign and date the informed consent form.
  • In need of an implant in position 16 to 26 or 36 to 46, and each subject can only receive one implant.
  • Deemed by the investigator as likely to present with an initially stable implant situation.
  • A stable occlusion, i.e. an opposing natural dentition, a crown, an implant-supported fixed or removable prosthesis, a partial removable prosthesis or a full denture.
  • An adjacent tooth (root with natural or artificial crown) or an implant-supported crown mesially and distally. Exemption: If the planned implant is in the first molar position, an edentulous space is accepted distally

Exclusion Criteria:

  • Not willing to participate in the clinical investigation or not able to understand the content of the clinical investigation.

  • Unlikely to be able to comply with clinical investigation procedures according to investigator's judgement.

  • Unable or unwilling to return for follow-up visits for a period of 5 years.

  • Known allergy or hypersensitivity to titanium and/or stainless steel.

  • Uncontrolled pathological process in the oral cavity, e.g. untreated rampant caries and uncontrolled periodontal disease.

  • Uncontrolled para-functional habits, e.g. bruxism.

  • Current need of any Guided Bone Regeneration (GBR) procedure in the planned implant area (gap filling at immediate placement and soft tissue grafting are allowed).

  • Systemic or local disease or condition that would compromise post-operative healing and/ or osseointegration.

  • Immunosuppression, use of corticosteroids, per-os or intravenous bisphosphonate use, or any other medication such as anti-resorptive therapy or monoclonal antibodies that could compromise post-operative healing and/or osseointegration.

  • Any other condition that would make the subject unsuitable for participation, including but not limited to;

    • History of radiation therapy in the head and neck region.
    • History of chemotherapy within 5 years prior to surgery.
    • Present alcohol and/or drug abuse.
    • Ongoing psychiatric illness.
    • Current smoking/use of tobacco, including e-cigarettes.
  • Any ongoing disease that would make the subject unsuitable for participation, including but not limited to;

    • Recent myocardial infarction (< 3 months*).
    • Recent cerebrovascular accident (< 3 months*).
    • Recent cardiac-valvular prosthesis placement (< 3 months*).
    • Hemorrhagic diathesis.
    • Severe liver dysfunction.
    • Known or suspected current malignancy.
    • Uncontrolled diabetes mellitus.
    • Florid infection.
  • Pregnant or breastfeeding females. (Pregnancy tests will be performed as per local requirements).

  • Previous enrolment in the present clinical investigation.

  • Involvement in the planning and conduct of the clinical investigation (applies to both Dentsply Sirona staff and the clinical investigation site).

  • Simultaneous participation in another clinical investigation, or participation in a clinical investigation during the last 6 months that may interfere with the present clinical investigation.

    • < 3 months is a strict exclusion criterion. After 3 month it is up to the investigator to judge whether the subject is considered suitable for participation or not.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: N / A
  • Modelo Intervencionista: Asignación de un solo grupo
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Single tooth restorations

A single, open-label group with patients in need of single tooth restorations will receive PrimeTaper EV implant system with diameters 3.6, 4.2, 4.8, 5.4 mm, and lengths 6.5, 8, 9, 11, 13, 15 and 17 mm.

Tapered dental implant developed by Dentsply Sirona

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Implant Survival, i.e. Number of Implants in Place Counted Clinically, 1 Year After Permanent Restoration.
Periodo de tiempo: One year post permanent restoration (anticipated average 3 months after implant placement).

Implant survival rate is a binary variable evaluated clinically, i.e. 'Yes' or 'No' where 'Yes' means that the implant is still in place and 'No' means that the implant is not in place. Any implant that has been removed or lost after implant placement visit will be considered a failure, whatever the reason for removal/loss.

One year post permanent restoration (anticipated average 3 months after implant placement).

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Implant Survival, i.e. Number of Implants in Place Counted Clinically, 2, 3, 4 and 5 Years After Permanent Restoration.
Periodo de tiempo: 2, 3, 4 and 5 years post permanent restoration (anticipated average 3 months after implant placement).

Implant survival rate is a binary variable evaluated clinically, i.e. 'Yes' or 'No' where 'Yes' means that the implant is still in place and 'No' means that the implant is not in place. Any implant that has been removed or lost after implant placement visit will be considered a failure, whatever the reason for removal/loss.

2, 3, 4 and 5 years post permanent restoration (anticipated average 3 months after implant placement).
Change of Implant Stability Quotient Value (ISQ) Between Implant Placement and Permanent Restoration.
Periodo de tiempo: From date of implant placement (anticipated average 1 month after inclusion) to date of permanent restoration (anticipated average 3 months after implant placement).

Implant stability will be evaluated through ISQ value using Resonance Frequency Analysis (RFA). The stability is presented as an ISQ value. The higher the ISQ value the higher the stability. Recorded as a numeric value (1-100).

From date of implant placement (anticipated average 1 month after inclusion) to date of permanent restoration (anticipated average 3 months after implant placement).
Maximum Insertion Torque Value for Each Implant at Implant Placement.
Periodo de tiempo: At date of implant placement (anticipated average 1 month after inclusion).

Maximum insertion torque value (ITV), based on ITV curve, measured in Ncm.

At date of implant placement (anticipated average 1 month after inclusion).
Final Insertion Torque Value for Each Implant at Implant Placement.
Periodo de tiempo: At date of implant placement (anticipated average 1 month after inclusion).

Final insertion torque value (ITV), based on ITV curve, measured in Ncm.

At date of implant placement (anticipated average 1 month after inclusion).
Investigator Questionnaire for Each Investigational Medical Device After Implant Placement.
Periodo de tiempo: Immediately after implant placement (anticipated average 1 month after inclusion).

Numerical scale 1-10, where 1 = totally disagree with the statement, and 10 = totally agree with the statement. Statements to be evaluated by the surgeon: "The implant was guided into the prepared osteotomy", "The implant followed the prepared osteotomy", "The implant has a good primary stability", "The drilling protocol is easy to use", "The implant has efficient cutting properties". Each statement will be evaluated separately.

Immediately after implant placement (anticipated average 1 month after inclusion).
Implant Success, i.e., Number of Implants Documented as Successful at 1, 2, 3 and 5 Years After Permanent Restoration.
Periodo de tiempo: 1, 2, 3 and 5 years post permanent restoration (anticipated average 3 months after implant placement).

Successful implants counted, i.e. 'Yes' or 'No'. An implant will be considered successful if all of the following criteria are fulfilled:

  1. Implant in place.
  2. Lack of evidence of peri-implant radiolucency in X-ray.
  3. Less than 1mm vertical bone loss during first year after loading with permanent restoration and 0,2mm annually thereafter.
  4. Absence of persistent and/or irreversible signs and symptoms such as pain, infections, neuropathies, paresthesia, or violation of the mandibular canal.
1, 2, 3 and 5 years post permanent restoration (anticipated average 3 months after implant placement).
Change of Marginal Bone Level up to 5 Years Post Permanent Restoration Compared to Permanent Restoration.
Periodo de tiempo: At permanent restoration (anticipated average 3 months after implant placement) and 1, 2, 3 and 5 years post permanent restoration.

MBL changes determined from radiographs, expressed as the distance from the implant reference point to the most coronal bone-to-implant contact on the mesial and distal side of the implant. The average will be calculated and compared for each evaluation period.

At permanent restoration (anticipated average 3 months after implant placement) and 1, 2, 3 and 5 years post permanent restoration.
Change of Probing Pocket Depth (PPD) in mm Between Permanent Restoration, and 6 Months, 1, 2, 3, 4 and 5 Years After Permanent Restoration.
Periodo de tiempo: At permanent restoration (anticipated average 3 months after implant placement) and 6 months, 1, 2, 3, 4 and 5 years post permanent restoration.

Probing Pocket Depth (PPD) measured as the distance from the mucosal margin to the bottom of the probe-able pocket in mm.

At permanent restoration (anticipated average 3 months after implant placement) and 6 months, 1, 2, 3, 4 and 5 years post permanent restoration.
Presence of Bleeding on Probing (BoP), at Permanent Restoration, and 6 Months, 1, 2, 3, 4 and 5 Years After Permanent Restoration.
Periodo de tiempo: At permanent restoration (anticipated average 3 months after implant placement) and 6 months, 1, 2, 3, 4 and 5 years post permanent restoration.

Bleeding on Probing (BoP) recorded as presence or absence of bleeding when probing to the bottom of the pocket.

At permanent restoration (anticipated average 3 months after implant placement) and 6 months, 1, 2, 3, 4 and 5 years post permanent restoration.
Presence of Plaque at 6 Months, 1, 2, 3, 4 and 5 Years After Permanent Restoration.
Periodo de tiempo: 6 months, 1, 2, 3, 4 and 5 years post permanent restoration (anticipated average 3 months after implant placement).

Plaque recorded as presence or absence of plaque by visual inspection on four surfaces at each implant site.

6 months, 1, 2, 3, 4 and 5 years post permanent restoration (anticipated average 3 months after implant placement).
Occurrence of Adverse Events, Adverse Device Effects, and Device Deficiencies During the Clinical Investigation.
Periodo de tiempo: Up to 5 years after permanent restoration (anticipated average 3 months after implant placement).

Adverse Events, Adverse Device Effects, and Device Deficiencies spontaneously reported, and collection at each clinical investigation visit.

Up to 5 years after permanent restoration (anticipated average 3 months after implant placement).

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Investigador principal: Andy Temmerman, Prof., KU Leuven

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

3 de mayo de 2022

Finalización primaria (Actual)

12 de marzo de 2025

Finalización del estudio (Estimado)

1 de mayo de 2029

Fechas de registro del estudio

Enviado por primera vez

16 de marzo de 2022

Primero enviado que cumplió con los criterios de control de calidad

6 de abril de 2022

Publicado por primera vez (Actual)

7 de abril de 2022

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

6 de octubre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

11 de septiembre de 2026

Última verificación

1 de septiembre de 2026

Más información

Términos relacionados con este estudio

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

Sí

producto fabricado y exportado desde los EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir